Skip to content

Alder migraine prevention med Phase 3 trial positive

June 27, 2017

Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine

* Says ‍​pivotal promise 1 top-line results show eptinezumab met primary and key secondary endpoints

* Says beginning day 1 after first dose, significant reduction in proportion of patients experiencing migraine

* Says average of 1 in 5 patients had no migraines in any given month over months 1 through 6

* Says Promise 1 met the primary endpoint, that is highly statistically significant reductions in monthly migraine days

* enrollment is on track for Promise 2; remains on track to submit BLA with FDA in second half of 2018


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: